Tegaserod-associated ischemic colitis

John K. DiBaise

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Tegaserod, a potent partial agonist of the serotonin 5-HT4 receptor, is used to treat women with constipation-predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.

Original languageEnglish (US)
Pages (from-to)620-625
Number of pages6
JournalPharmacotherapy
Volume25
Issue number4
DOIs
StatePublished - Apr 1 2005

    Fingerprint

Keywords

  • IBS
  • Irritable bowel syndrome
  • Ischemic colitis
  • Tegaserod

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this